Nexalin Technology announced acceptance of two clinical abstracts for the 2026 NYC Neuromodulation Conference, highlighting its proprietary DIFS™ neurostimulation platform. The clinical trial in Brazil showed a 77.8% anxiety response rate, significant improvements in depression, insomnia, and quality of life, with benefits lasting through an 8-week follow-up. No serious adverse events were reported, supporting Nexalin's non-invasive approach as a promising treatment for neuropsychiatric conditions. The company plans to advance regulatory and commercial efforts, including a potential product launch in Brazil.
Bitcoin miners are experiencing declining revenue as the network's hash rate and mining difficulty fall, reflecting a shift of miners into AI infrastructure. Despite this stress, miners are accumulating Bitcoin, with reserves increasing by 1%, signal...
Lululemon invested in Syntetica's $30 million Series A funding to support its innovative recycling of Nylon 6 and Nylon 6,6, materials difficult to separate and reuse in textile waste. This move aligns with growing industry demand for sustainable, co...
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
